What are the side effects of Prolia (denosumab)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Prolia (denosumab) can cause several side effects, including jaw bone problems, unusual thigh bone fractures, and low calcium levels, and patients should be aware of these potential risks and take steps to mitigate them, such as maintaining good dental hygiene and ensuring adequate calcium and vitamin D intake 1.

Common Side Effects

  • Back pain
  • Arm and leg pain
  • High cholesterol
  • Musculoskeletal pain
  • Bladder infections

Serious Side Effects

  • Jaw bone problems (osteonecrosis)
  • Unusual thigh bone fractures
  • Serious infections
  • Skin problems
  • Severe bone/joint/muscle pain
  • Low calcium levels

Allergic Reactions

  • Rash
  • Itching
  • Swelling

Mechanism and Prevention

Prolia works by blocking a protein called RANKL, which helps prevent bone breakdown, but this mechanism can also lead to these side effects. Patients should maintain good dental hygiene while on Prolia due to the risk of jaw problems, ensure adequate calcium and vitamin D intake to prevent hypocalcemia, and report any thigh or groin pain promptly. It's essential to discuss all potential side effects with your doctor before starting Prolia and report any concerning symptoms during treatment 1.

Monitoring and Treatment

Monitoring of creatinine clearance is required to guide dosing of zoledronic acid, and denosumab may be administered to patients with impaired renal function or even patients on hemodialysis, but with caution and close monitoring for severe hypocalcemia and hypophosphatemia 1.

Recommendations

The NCCN Guidelines for MM recommend bisphosphonates (category 1) or denosumab for all patients receiving therapy for symptomatic MM regardless of documented bone disease, and denosumab is preferred in patients with renal disease 1.

From the FDA Drug Label

Prolia may cause serious side effects including: Increased risk of severe low calcium levels in your blood (hypocalcemia). Serious allergic reactions. Severe jaw bone problems (osteonecrosis). Unusual thigh bone fractures. Increased risk of broken bones, including broken bones in the spine, after stopping, skipping or delaying Prolia. Serious infections. Dermatologic Adverse Reactions Musculoskeletal Pain

The possible side effects of Prolia include:

  • Hypocalcemia: increased risk of severe low calcium levels in the blood
  • Allergic reactions: serious allergic reactions, including anaphylaxis, rash, urticaria, facial swelling, and erythema
  • Osteonecrosis: severe jaw bone problems
  • Atypical fractures: unusual thigh bone fractures
  • Infections: serious infections, including cellulitis and endocarditis
  • Dermatologic reactions: dermatitis, eczema, and rashes
  • Musculoskeletal pain: severe bone, joint, and/or muscle pain
  • Common side effects:
    • Back pain
    • Pain in arms and legs
    • High cholesterol
    • Muscle pain
    • Bladder infection
    • Joint pain
    • Common cold
    • Lung infection
    • Headache
    • Pain in extremity
    • Musculoskeletal pain
    • Cataracts (in men with nonmetastatic prostate cancer receiving ADT) 2 2 2

From the Research

Prolia Side Effects

Prolia, also known as denosumab, is a medication used to treat osteoporosis and various malignancies. The following are some of the known side effects of Prolia:

  • Hypocalcemia (low calcium levels in the blood) 3, 4, 5, 6, 7
  • Hypophosphatemia (low phosphate levels in the blood) 3, 5
  • Electrolyte abnormalities 3

Risk Factors for Hypocalcemia

Several studies have identified risk factors for hypocalcemia in patients taking Prolia, including:

  • Age ≥65 years 4
  • Grade 1 or higher serum alkaline phosphatase elevation 4
  • Adjusted serum calcium level of less than 9.3 mg/dL at baseline 4
  • Co-administration of cytotoxic agents 4
  • Pretreatment serum calcium and creatinine levels 7
  • Decreased estimated glomerular filtration rate (eGFR) 6, 7

Management of Hypocalcemia

The management of hypocalcemia in patients taking Prolia typically involves:

  • Discontinuation of denosumab 5
  • Intravenous (IV) and oral mineral supplementation 3, 5
  • Calcium and vitamin D supplementation 4, 7
  • Close monitoring of electrolyte levels 3, 4, 5, 6, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2023

Research

Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.